Biologic Therapies for Rheumatoid Arthritis Targeting TNF-α and IL-1
作者： P. C. Taylor
DOI: 10.1007/978-3-540-29018-6_11
关键词:
摘要: ‘Biologics’ are protein-based drugs derived from living organisms and designed to either inhibit or augment a specific component of the immune system. Examples include antibodies directed against very molecular components response, for example, pro-inflammatory cytokines, naturally occurring cytokine inhibitors such as IL-1 receptor antagonist (IL-1ra).
springer.com
sci-hub.st 参考文章(66)
D M Butler, R N Maini, M Feldmann, F M Brennan, Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. European Cytokine Network. ,vol. 6, pp. 225- 230 ,(1995)
J. Keffer, L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, G. Kollias, Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. The EMBO Journal. ,vol. 10, pp. 4025- 4031 ,(1991) , 10.1002/J.1460-2075.1991.TB04978.X
Richard O. Williams, Lilia Marinova-Mutafchieva, Marc Feldmann, Ravinder N. Maini, Evaluation of TNF-α and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-α/Anti-CD4 Therapy The Journal of Immunology. ,vol. 165, pp. 7240- 7245 ,(2000) , 10.4049/JIMMUNOL.165.12.7240
J R Kalden, H M Lorenz, N Schwerdtner, C Antoni, R Repp, J Woody, T Valerius, B Manger, M Grünke, H Nüsslein, In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short-term cellular and molecular effects Journal of Immunology. ,vol. 156, pp. 1646- 1653 ,(1996)
P. C. Taylor, A. Steuer, J. Gruber, D. O. Cosgrove, M. J. K. Blomley, P. A. Marsters, C. L. Wagner, C. McClinton, R. N. Maini, Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis† Arthritis & Rheumatism. ,vol. 50, pp. 1107- 1116 ,(2004) , 10.1002/ART.20123
Josef S. Smolen, Chenglong Han, Désirée Van Der Heijde, Paul Emery, Joan M. Bathon, Edward Keystone, Joachim R. Kalden, Michael Schiff, Mohan Bala, Daniel Baker, John Han, Ravinder N. Maini, E. William St.Clair, Infliximab treatment maintains employability in patients with early rheumatoid arthritis Arthritis & Rheumatism. ,vol. 54, pp. 716- 722 ,(2006) , 10.1002/ART.21661
Barry Bresnihan, Jos� Maria Alvaro-Gracia, Mark Cobby, Michael Doherty, Zlatko Domljan, Paul Emery, George Nuki, Karel Pavelka, Rolf Rau, Blaz Rozman, Iain Watt, Bryan Williams, Roger Aitchison, Dorothy McCabe, Predrag Musikic, Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist Arthritis & Rheumatism. ,vol. 41, pp. 2196- 2204 ,(1998) , 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2
Ann-Kristin Ulfgren, Ulf Andersson, Marianne Engström, Lars Klareskog, Ravinder N. Maini, Peter C. Taylor, Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis & Rheumatism. ,vol. 43, pp. 2391- 2396 ,(2000) , 10.1002/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F
Maria Ziolkowska, Mariola Kurowska, Anna Radzikowska, Grazyna Luszczykiewicz, Piotr Wiland, Wojciech Dziewczopolski, Anna Filipowicz-Sosnowska, Jacek Pazdur, Jacek Szechinski, Jacek Kowalczewski, Maria Rell-Bakalarska, Wlodzimierz Maslinski, High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis & Rheumatism. ,vol. 46, pp. 1744- 1753 ,(2002) , 10.1002/ART.10388
Ravinder Maini, E William St Clair, Ferdinand Breedveld, Daniel Furst, Joachim Kalden, Michael Weisman, Josef Smolen, Paul Emery, Gregory Harriman, Marc Feldmann, Peter Lipsky, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial The Lancet. ,vol. 354, pp. 1932- 1939 ,(1999) , 10.1016/S0140-6736(99)05246-0